|
Parkinson Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Calb1 has received attention for a potential role in neuroprotection in Parkinson's disease.
|
31361457 |
2019 |
|
Parkinson Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Thus, calbindin-positive and calbindin-negative SNc neurons differ substantially in their calcium channel composition and efficacy of excitatory inputs in the presence of dopamine inhibition.<b>SIGNIFICANCE STATEMENT</b> Substantia nigra dopaminergic neurons can be divided into two populations: the calbindin-negative ventral tier, which is vulnerable to neurodegeneration in Parkinson's disease, and the calbindin-positive dorsal tier, which is relatively resilient.
|
28264982 |
2017 |
|
Parkinson Disease
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that targeting raised intraneuronal-free Ca(II) in the brain by promoting the expression of calbindin-D28k at the transcriptional level using calcipotriol could prevent α-synuclein aggregate formation and ameliorate Parkinson's disease pathogenesis.
|
28164279 |
2017 |
|
Parkinson Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
This suggests the effect of calbindin on PD risk displays population specificity.
|
19674066 |
2010 |
|
Parkinson Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Our genetic analysis suggests that CALB1 is associated with PD independently of SNCA, and that FGF20 is associated with PD synergistically with SNCA.
|
18568448 |
2008 |
|
Parkinson Disease
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
We go on to describe variations in vulnerability to neurotoxic damage in models of Parkinson's disease in subgroups of DA neurons and its possible relationship to developmental gene regulation, the expression of different ion channels, and the expression of different protein markers, such as the neuroprotective marker calbindin.
|
15181237 |
2004 |
|
Parkinson Disease
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Comparison of diseased human brain tissue with age- and sex-matched controls yielded significant decreases (60-88%) in calbindin protein and mRNA in the substantia nigra (Parkinson disease), in the corpus striatum (Huntington disease), in the nucleus basalis (Alzheimer disease), and in the hippocampus and nucleus raphe dorsalis (Parkinson, Huntington, and Alzheimer diseases) but not in the cerebellum, neocortex, amygdala, or locus ceruleus.
|
2140897 |
1990 |
|
Huntington Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Upregulation of striatal proteins that regulate calcium, including calbindin and homer1a, upon chronic therapy with pridopidine, may further contribute to long-term beneficial effects of pridopidine in HD.
|
27818324 |
2017 |
|
Huntington Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
We examined mitochondria in preferentially vulnerable striatal calbindin-positive neurons in moderate-to-severe grade HD patients, using antisera against mitochondrial markers of COX2, SOD2 and cytochrome c. Combined calbindin and mitochondrial marker immunofluorescence showed a significant and progressive grade-dependent reduction in the number of mitochondria in spiny striatal neurons, with marked alteration in size.
|
20660112 |
2010 |
|
Huntington Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
We used immunolabeling to assess if calbindin is elevated in striatal projection neurons of R6/2 HD transgenic mice.
|
15990326 |
2005 |
|
Huntington Disease
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
No decline in calbindin D28k mRNA levels per neuron were found in HD striata compared to control striata.
|
8526457 |
1995 |
|
Huntington Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Comparison of diseased human brain tissue with age- and sex-matched controls yielded significant decreases (60-88%) in calbindin protein and mRNA in the substantia nigra (Parkinson disease), in the corpus striatum (Huntington disease), in the nucleus basalis (Alzheimer disease), and in the hippocampus and nucleus raphe dorsalis (Parkinson, Huntington, and Alzheimer diseases) but not in the cerebellum, neocortex, amygdala, or locus ceruleus.
|
2140897 |
1990 |
|
Impaired cognition
|
0.040 |
Biomarker
|
disease |
BEFREE |
Heterochronic parabiosis (shared blood circulation) of AD transgenic mice with young healthy mice did not reduce amyloidosis and microglial activation in AD mice, but reversed the loss of synaptophysin and calbindin (critical synaptic proteins, indicators of cognitive decline in AD) in the dentate gyrus, and the abnormal expression, in the hippocampus, of many genes involved in key neuronal signaling pathways.
|
28384033 |
2018 |
|
Impaired cognition
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
GM-CSF treatment in AD mice reduced brain amyloidosis, increased plasma Aβ, and rescued cognitive impairment with increased hippocampal expression of calbindin and synaptophysin and increased levels of doublecortin-positive cells in the dentate gyrus.
|
29573847 |
2018 |
|
Impaired cognition
|
0.040 |
Biomarker
|
disease |
BEFREE |
We propose that chronic suppression of calbindin by ΔFosB is one mechanism through which intermittent seizures drive persistent cognitive deficits in conditions accompanied by recurrent seizures.
|
29035369 |
2017 |
|
Impaired cognition
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In this study, we explored a possible link between cognitive dysfunction and hippocampal expression of calbindin D(28KD) (CB), a high affinity calcium-binding protein, in four MELAS patients, using post mortem hippocampal tissues.
|
22483853 |
2012 |
|
Memory impairment
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
The aim of this study was to determine the CB immunoreactivity in hippocampal dentate gyrus of patients who underwent epilepsy surgery for drug-resistant TLE with and without comorbid depression and/or memory deficits.
|
31191739 |
2019 |
|
Memory impairment
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
We hypothesized that, despite TH, neonatal HI persistently decreases Calb1 expression in the hippocampus, a change associated with memory deficits in the mouse.
|
30861522 |
2019 |
|
Memory impairment
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
These results indicate that the dysregulation of calbindin in hippocampal excitatory, but not inhibitory, neurons conveys susceptibility to stress-induced memory deficits.
|
29069596 |
2017 |
|
Mental disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
Calbindin-containing γ-aminobutyric acid (GABA)ergic interneurons in the prefrontal cortex (PFC) have been found to play an important role in working memory (WM) and their malfunctions have been linked to psychiatric disorders.
|
26249043 |
2015 |
|
Abnormal behavior
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Calbindin-containing γ-aminobutyric acid (GABA)ergic interneurons in the prefrontal cortex (PFC) have been found to play an important role in working memory (WM) and their malfunctions have been linked to psychiatric disorders.
|
26249043 |
2015 |
|
Mental disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
We explored the possible genetic causalities that may underlie the cytoarchitectural abnormalities of calbindin-containing γ-aminobutyric acid (GABA)ergic neurons and perineuronal oligodendrocytes in the PFC of subjects with psychiatric disorders by converging results from genome-wide single-nucleotide polymorphism (SNP) scans for the traits and expression SNP (eSNP) associations.
|
20308991 |
2011 |
|
Abnormal behavior
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
We explored the possible genetic causalities that may underlie the cytoarchitectural abnormalities of calbindin-containing γ-aminobutyric acid (GABA)ergic neurons and perineuronal oligodendrocytes in the PFC of subjects with psychiatric disorders by converging results from genome-wide single-nucleotide polymorphism (SNP) scans for the traits and expression SNP (eSNP) associations.
|
20308991 |
2011 |
|
Mental disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
These findings may provide novel insights into the molecular mechanisms that underlie the cytoarchitectural abnormalities of perineuronal oligodendrocytes and calbindin-containing GABAergic interneurons in the prefrontal cortex of the major psychiatric disorders.
|
18762803 |
2010 |
|
Abnormal behavior
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
These findings may provide novel insights into the molecular mechanisms that underlie the cytoarchitectural abnormalities of perineuronal oligodendrocytes and calbindin-containing GABAergic interneurons in the prefrontal cortex of the major psychiatric disorders.
|
18762803 |
2010 |